var data={"title":"Metachromatic leukodystrophy","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Metachromatic leukodystrophy</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/contributors\" class=\"contributor contributor_credentials\">Raphael Schiffmann, MD, MHSc</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/contributors\" class=\"contributor contributor_credentials\">Marc C Patterson, MD, FRACP</a></dd><dd><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/contributors\" class=\"contributor contributor_credentials\">Helen V Firth, DM, FRCP, DCH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/contributors\" class=\"contributor contributor_credentials\">John F Dashe, MD, PhD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 05, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Metachromatic leukodystrophy (sulfatide lipidosis) (MLD) is a rare autosomal recessive lysosomal storage disease that causes progressive demyelination of the central and peripheral nervous system.</p><p>This topic will review the clinical manifestations, diagnosis, and treatment of metachromatic leukodystrophy. Other lysosomal storage disorders and leukodystrophies are discussed separately. (See <a href=\"topic.htm?path=adrenoleukodystrophy\" class=\"medical medical_review\">&quot;Adrenoleukodystrophy&quot;</a> and <a href=\"topic.htm?path=alexander-disease\" class=\"medical medical_review\">&quot;Alexander disease&quot;</a> and <a href=\"topic.htm?path=aspartoacylase-deficiency-canavan-disease\" class=\"medical medical_review\">&quot;Aspartoacylase deficiency (Canavan disease)&quot;</a> and <a href=\"topic.htm?path=cerebrotendinous-xanthomatosis\" class=\"medical medical_review\">&quot;Cerebrotendinous xanthomatosis&quot;</a> and <a href=\"topic.htm?path=fabry-disease-neurologic-manifestations\" class=\"medical medical_review\">&quot;Fabry disease: Neurologic manifestations&quot;</a> and <a href=\"topic.htm?path=krabbe-disease\" class=\"medical medical_review\">&quot;Krabbe disease&quot;</a> and <a href=\"topic.htm?path=mucopolysaccharidoses-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Mucopolysaccharidoses: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=overview-of-niemann-pick-disease\" class=\"medical medical_review\">&quot;Overview of Niemann-Pick disease&quot;</a> and <a href=\"topic.htm?path=pelizaeus-merzbacher-disease\" class=\"medical medical_review\">&quot;Pelizaeus-Merzbacher disease&quot;</a> and <a href=\"topic.htm?path=sjogren-larsson-syndrome\" class=\"medical medical_review\">&quot;Sj&ouml;gren-Larsson syndrome&quot;</a> and <a href=\"topic.htm?path=vanishing-white-matter-disease\" class=\"medical medical_review\">&quot;Vanishing white matter disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H977153559\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Metachromatic leukodystrophy (MLD) is caused by deficient activity of arylsulfatase A as a result of, in almost all cases, mutations in the arylsulfatase A gene (ARSA gene). In a few patients, MLD is caused by a deficiency of sphingolipid activator protein SAP-B (saposin B), which normally stimulates the degradation of sulfatides by ARSA [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/1\" class=\"abstract_t\">1</a>]. This variant form of MLD is caused by mutations in the prosaposin gene (PSAP gene).</p><p>ARSA is responsible for the desulfation of cerebroside sulfate, a major glycolipid of myelin. As a result, decreased ARSA activity leads to the accumulation of cerebroside sulfate in the central nervous system, peripheral nerves, kidneys, and other visceral organs. The accumulation of cerebroside sulfate destroys oligodendroglial and Schwann cells, causing central and peripheral demyelination. Electron microscopy shows thickened lines in the myelin whorls and lamellar inclusions of sulfatides in the Schwann cells [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h2\">Genetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>At least 60 mutations in the ARSA gene have been described in MLD. Two alleles, A and I, together account for approximately 50 percent of cases [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/3,4\" class=\"abstract_t\">3,4</a>]. These alleles contribute to the different clinical expressions of the disease [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Homozygosity for the I allele is associated with very low or undetectable residual ARSA activity and late infantile onset; compound heterozygotes (with the other allele unknown) also appear to have a late infantile onset.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Homozygosity for the A allele is associated with low but detectable residual ARSA activity and the juvenile or adult onset forms; compound heterozygotes have later onset of disease.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The presence of both alleles is associated with juvenile onset.</p><p/><p>There is evidence for a correlation between genotype and phenotype in late-onset MLD, a category that includes late juvenile and adult onset [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/5\" class=\"abstract_t\">5</a>]. Patients who are homozygous for ARSA mutation P426L generally present with progressive gait disturbance (spastic paraparesis or cerebellar ataxia), while mental involvement becomes evident later. In contrast, compound heterozygotes for ARSA mutation I179S present with schizophrenia-like behavioral abnormalities, social dysfunction, and mental decline, but motor deficits are scarce. (See <a href=\"#H5\" class=\"local\">'Juvenile and adult onset'</a> below.)</p><p>Some normal individuals have low ARSA activity approximating those of patients with MLD. This nonpathogenic reduction in ARSA activity is caused by homozygosity for the ARSA pseudodeficiency allele. This allele contains two sequence alterations, a polyadenylation defect and an amino acid substitution. The combined effect of these changes is to reduce ARSA activity to approximately 8 percent of normal [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/6\" class=\"abstract_t\">6</a>]. The frequency of the allele is about 10 percent in most populations, resulting in a 1 percent frequency of the pseudodeficiency phenotype [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/6,7\" class=\"abstract_t\">6,7</a>].</p><p class=\"headingAnchor\" id=\"H988968878\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prevalence of metachromatic leukodystrophy (MLD) ranges from 1:40,000 to 1:100,000 in northern European and North American populations [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/8,9\" class=\"abstract_t\">8,9</a>]. However, a higher prevalence has been found in certain groups including Habbanite Jews in Israel, Arabs living in Israel, and Navajo Indians in the United States [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/10-12\" class=\"abstract_t\">10-12</a>].</p><p>In a retrospective review of 122 children with an inherited leukodystrophy from a regional center in Utah, MLD was the etiology in 8 percent, making it the most common diagnosis, similar in frequency to Pelizaeus-Merzbacher disease (7 percent), and higher in frequency than mitochondrial diseases (5 percent) or adrenoleukodystrophy (4 percent) [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/13\" class=\"abstract_t\">13</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Three major subtypes of metachromatic leukodystrophy (MLD) are primarily distinguished by the age at disease onset [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/3\" class=\"abstract_t\">3</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Late infantile onset (age 6 months to 2 years)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Juvenile onset (age 3 to 16 years)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adult onset (age &gt;16)</p><p/><p>Peripheral neuropathy occurs in all forms and may be a presenting feature, particularly in the late infantile form (<a href=\"image.htm?imageKey=PEDS%2F56567\" class=\"graphic graphic_table graphicRef56567 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/14-16\" class=\"abstract_t\">14-16</a>]. Gallbladder involvement is common with manifestations that include hyperplastic polyps and a probable increased risk of gallbladder carcinoma [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/17-21\" class=\"abstract_t\">17-21</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Late infantile onset</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The late infantile form of MLD typically appears at six months to two years of age, though onset up to age four is considered late infantile by some investigators [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/22\" class=\"abstract_t\">22</a>]. Early signs include regression of motor skills, gait difficulties, seizures, ataxia, hypotonia, extensor plantar responses, and optic atrophy [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/22,23\" class=\"abstract_t\">22,23</a>]. Deep tendon reflexes are sometimes reduced or absent, reflecting a peripheral neuropathy. The prognosis is worse than later onset forms of MLD; progression to death typically occurs within five to six years.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Juvenile and adult onset</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The juvenile onset form of MLD is heterogeneous in presentation. Some children present between four and six years of age (early juvenile) with, intellectual impairment, behavioral difficulties, gait disturbance, ataxia, upper motor neuron signs, and a peripheral neuropathy [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/22,24\" class=\"abstract_t\">22,24</a>]. Seizures may occur, and progression to death occurs within six years of onset. Another group of children present between 6 and 16 years of age (late juvenile) with behavioral changes and intellectual impairment and, in many cases, seizures. Progression is slower, and these children may survive until early adulthood.</p><p>Adult onset MLD (age 17 or older) is usually heralded by dementia and behavioral difficulties, and a substantial minority present with neuropathy, psychosis, schizophrenia, or seizures [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/22\" class=\"abstract_t\">22</a>]. Optic atrophy has also been reported [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/25\" class=\"abstract_t\">25</a>].</p><p class=\"headingAnchor\" id=\"H1048028759\"><span class=\"h2\">Investigations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In late-onset MLD, nerve conduction studies show marked slowing. Sensory potentials are affected earlier and more severely than are motor responses [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/26,27\" class=\"abstract_t\">26,27</a>]. There is segmental demyelination with metachromatic material in Schwann cells and macrophages on peripheral nerve biopsy [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/28,29\" class=\"abstract_t\">28,29</a>].</p><p>Brain MRI reveals symmetric white matter lesions with a periventricular predominance in the early form of the disease and cortical atrophy in the later forms (<a href=\"image.htm?imageKey=NEURO%2F65871\" class=\"graphic graphic_algorithm graphicRef65871 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/30\" class=\"abstract_t\">30</a>]. A retrospective study reported that levels of N-acetylaspartate (NAA) measured by magnetic resonance spectroscopy may be useful in therapeutic trials as a biomarker of MLD disease progression [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/31\" class=\"abstract_t\">31</a>], but the utility of NAA levels in clinical practice is not established.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical picture combined with reduced nerve conduction velocity and elevated cerebrospinal fluid protein concentrations should suggest the diagnosis of metachromatic leukodystrophy (MLD).</p><p>The diagnosis of MLD is established by demonstrating deficient arylsulfatase A gene (ARSA gene) activity in leukocytes or cultured skin fibroblasts. Values typically range from undetectable to less than 10 percent of normal values. However, diagnosis based only on the activity of ARSA is complicated by the existence of ARSA pseudodeficiency (present in approximately one percent of the general population). As a result, screening for the presence of the pseudodeficiency alleles is important when low but not absent levels are detected in prenatal testing or screening of asymptomatic relatives [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/7\" class=\"abstract_t\">7</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No curative treatment is currently available for metachromatic leukodystrophy (MLD). Allogeneic hematopoietic cell transplantation has slowed disease progression in some patients [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/32-35\" class=\"abstract_t\">32-35</a>].</p><p>Preliminary evidence suggests that gene therapy, hematopoietic stem cell transplantation combined with gene therapy, and enzyme replacement therapy are promising treatment options [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/36\" class=\"abstract_t\">36</a>].</p><p>In the first clinical application, lentiviral vectors were used to transfer functional ARSA genes into autologous hematopoietic stem cells (HSCs) from three presymptomatic infants (ages 7 to 16 months) with genetic, biochemical, and electrodiagnostic evidence of late infantile MLD [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/37\" class=\"abstract_t\">37</a>]. The gene-corrected HSCs were then transfused back into the patients. The treatment resulted in stable engraftment of the transduced HSCs and high levels of ARSA activity. At 7 to 21 months of follow-up beyond the predicted age of symptom onset, all three patients showed normal motor and cognitive development with no evidence of disease progression and no signs of vector-induced genotoxicity. A subsequent study from the same investigators reported outcomes at 1.5 to 4.5 years for the first nine children treated, with prevention of symptom onset or a halt in disease progression noted in eight children [<a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/38\" class=\"abstract_t\">38</a>]. While these results are promising, longer follow-up in more patients is needed to confirm the safety and benefit of this therapy.</p><p class=\"headingAnchor\" id=\"H977153517\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disease caused by mutations in the arylsulfatase A gene (ARSA gene). In a few patients, a variant form of MLD is caused by mutations in the prosaposin gene (PSAP gene). (See <a href=\"#H977153559\" class=\"local\">'Etiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The prevalence of MLD ranges from 1:40,000 to 1:100,000 in northern European and North American populations. (See <a href=\"#H988968878\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Three major subtypes of MLD are primarily distinguished by the age at disease onset and include late infantile, juvenile, and adult forms. (See <a href=\"#H3\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The late infantile form of MLD presents from age six months to two years; early signs include regression of motor skills, gait difficulty, ataxia, hypotonia, extensor plantar responses, optic atrophy, and peripheral neuropathy. (See <a href=\"#H4\" class=\"local\">'Late infantile onset'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The juvenile form of MLD presents between 3 and 16 years of age with gait disturbance, intellectual impairment, ataxia, upper motor neuron signs, and a peripheral neuropathy. Seizures may occur. Adult onset MLD (age 17 or older) is usually heralded by dementia and behavioral difficulties. (See <a href=\"#H5\" class=\"local\">'Juvenile and adult onset'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of MLD is established by demonstrating deficient ARSA activity in leukocytes or cultured skin fibroblasts. However, diagnosis based only on the activity of ARSA is complicated by the existence of ARSA pseudodeficiency. (See <a href=\"#H6\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No curative treatment is currently available for MLD. Investigational treatments include bone marrow transplantation, gene therapy, or hematopoietic stem cell transplantation combined with gene therapy. (See <a href=\"#H7\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H142975942\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Robert Cruse, DO, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/1\" class=\"nounderline abstract_t\">Wrobe D, Henseler M, Huettler S, et al. A non-glycosylated and functionally deficient mutant (N215H) of the sphingolipid activator protein B (SAP-B) in a novel case of metachromatic leukodystrophy (MLD). J Inherit Metab Dis 2000; 23:63.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/2\" class=\"nounderline abstract_t\">Thomas PK, King RH, Kocen RS, Brett EM. Comparative ultrastructural observations on peripheral nerve abnormalities in the late infantile, juvenile and late onset forms of metachromatic leukodystrophy. Acta Neuropathol 1977; 39:237.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/3\" class=\"nounderline abstract_t\">Polten A, Fluharty AL, Fluharty CB, et al. Molecular basis of different forms of metachromatic leukodystrophy. N Engl J Med 1991; 324:18.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/4\" class=\"nounderline abstract_t\">Berger J, L&ouml;schl B, Bernheimer H, et al. Occurrence, distribution, and phenotype of arylsulfatase A mutations in patients with metachromatic leukodystrophy. Am J Med Genet 1997; 69:335.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/5\" class=\"nounderline abstract_t\">Rauschka H, Colsch B, Baumann N, et al. Late-onset metachromatic leukodystrophy: genotype strongly influences phenotype. Neurology 2006; 67:859.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/6\" class=\"nounderline abstract_t\">Harvey JS, Carey WF, Morris CP. Importance of the glycosylation and polyadenylation variants in metachromatic leukodystrophy pseudodeficiency phenotype. Hum Mol Genet 1998; 7:1215.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/7\" class=\"nounderline abstract_t\">Barth ML, Ward C, Harris A, et al. Frequency of arylsulphatase A pseudodeficiency associated mutations in a healthy population. J Med Genet 1994; 31:667.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/8\" class=\"nounderline abstract_t\">Gustavson KH, Hagberg B. The incidence and genetics of metachromatic leucodystrophy in northern Sweden. Acta Paediatr Scand 1971; 60:585.</a></li><li class=\"breakAll\">Von Figura K, Gieselmann V, Jacken J. Metachromatic leukodystrophy. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.3695.</li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/10\" class=\"nounderline abstract_t\">Zlotogora J, Bach G, Barak Y, Elian E. Metachromatic leukodystrophy in the habbanite Jews: high frequency in a genetic isolate and screening for heterozygotes. Am J Hum Genet 1980; 32:663.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/11\" class=\"nounderline abstract_t\">Heinisch U, Zlotogora J, Kafert S, Gieselmann V. Multiple mutations are responsible for the high frequency of metachromatic leukodystrophy in a small geographic area. Am J Hum Genet 1995; 56:51.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/12\" class=\"nounderline abstract_t\">Holve S, Hu D, McCandless SE. Metachromatic leukodystrophy in the Navajo: fallout of the American-Indian wars of the nineteenth century. Am J Med Genet 2001; 101:203.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/13\" class=\"nounderline abstract_t\">Bonkowsky JL, Nelson C, Kingston JL, et al. The burden of inherited leukodystrophies in children. Neurology 2010; 75:718.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/14\" class=\"nounderline abstract_t\">Malone MJ, Stoffyn P. Peripheral nerve glycolipids in metachromatic leukodystrophy. Neurology 1967; 17:1033.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/15\" class=\"nounderline abstract_t\">Fressinaud C, Vallat JM, Masson M, et al. Adult-onset metachromatic leukodystrophy presenting as isolated peripheral neuropathy. Neurology 1992; 42:1396.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/16\" class=\"nounderline abstract_t\">Cameron CL, Kang PB, Burns TM, et al. Multifocal slowing of nerve conduction in metachromatic leukodystrophy. Muscle Nerve 2004; 29:531.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/17\" class=\"nounderline abstract_t\">Ries M, Deeg KH. Polyposis of the gallbladder associated with metachromatic leukodystrophy. Eur J Pediatr 1993; 152:450.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/18\" class=\"nounderline abstract_t\">Simanovsky N, Ackerman Z, Kiderman A, Fields S. Unusual gallbladder findings in two brothers with metachromatic leukodystrophy. Pediatr Radiol 1998; 28:706.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/19\" class=\"nounderline abstract_t\">Cappell MS, Marks M, Kirschenbaum H. Massive hemobilia and acalculous cholecystitis due to benign gallbladder polyp. Dig Dis Sci 1993; 38:1156.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/20\" class=\"nounderline abstract_t\">Garavelli L, Rosato S, Mele A, et al. Massive hemobilia and papillomatosis of the gallbladder in metachromatic leukodystrophy: a life-threatening condition. Neuropediatrics 2009; 40:284.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/21\" class=\"nounderline abstract_t\">van Rappard DF, Bugiani M, Boelens JJ, et al. Gallbladder and the risk of polyps and carcinoma in metachromatic leukodystrophy. Neurology 2016; 87:103.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/22\" class=\"nounderline abstract_t\">Mahmood A, Berry J, Wenger DA, et al. Metachromatic leukodystrophy: a case of triplets with the late infantile variant and a systematic review of the literature. J Child Neurol 2010; 25:572.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/23\" class=\"nounderline abstract_t\">Zafeiriou DI, Kontopoulos EE, Michelakakis HM, et al. Neurophysiology and MRI in late-infantile metachromatic leukodystrophy. Pediatr Neurol 1999; 21:843.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/24\" class=\"nounderline abstract_t\">MacFaul R, Cavanagh N, Lake BD, et al. Metachromatic leucodystrophy: review of 38 cases. Arch Dis Child 1982; 57:168.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/25\" class=\"nounderline abstract_t\">Quigley HA, Green WR. Clinical and ultrastructural ocular histopathologic studies of adult-onset metachromatic leukodystrophy. Am J Ophthalmol 1976; 82:472.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/26\" class=\"nounderline abstract_t\">Takakura H, Nakano C, Kasagi S, et al. Multimodality evoked potentials in progression of metachromatic leukodystrophy. Brain Dev 1985; 7:424.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/27\" class=\"nounderline abstract_t\">Wulff CH, Trojaborg W. Adult metachromatic leukodystrophy: neurophysiologic findings. Neurology 1985; 35:1776.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/28\" class=\"nounderline abstract_t\">Dayan AD. Peripheral neuropathy of metachromatic leucodystrophy: observations on segmental demyelination and remyelination and the intracellular distribution of sulphatide. J Neurol Neurosurg Psychiatry 1967; 30:311.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/29\" class=\"nounderline abstract_t\">Luijten JA, Straks W, Blikkendaal-Lieftinck LF, et al. Metachromatic leukodystrophy: a comparative study of the ultrastructural findings in the peripheral nervous system of three cases, one of the late infantile, one of the juvenile and one of the adult form of the disease. Neuropadiatrie 1978; 9:338.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/30\" class=\"nounderline abstract_t\">Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology 2009; 72:750.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/31\" class=\"nounderline abstract_t\">i Dali C, Hanson LG, Barton NW, et al. Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy. Neurology 2010; 75:1896.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/32\" class=\"nounderline abstract_t\">Solders M, Martin DA, Andersson C, et al. Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy. Bone Marrow Transplant 2014; 49:1046.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/33\" class=\"nounderline abstract_t\">de Hosson LD, van de Warrenburg BP, Preijers FW, et al. Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literature. Bone Marrow Transplant 2011; 46:1071.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/34\" class=\"nounderline abstract_t\">Boucher AA, Miller W, Shanley R, et al. Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. Orphanet J Rare Dis 2015; 10:94.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/35\" class=\"nounderline abstract_t\">Groeschel S, K&uuml;hl JS, Bley AE, et al. Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Juvenile Metachromatic Leukodystrophy Compared With Nontransplanted Control Patients. JAMA Neurol 2016; 73:1133.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/36\" class=\"nounderline abstract_t\">Batzios SP, Zafeiriou DI. Developing treatment options for metachromatic leukodystrophy. Mol Genet Metab 2012; 105:56.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/37\" class=\"nounderline abstract_t\">Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013; 341:1233158.</a></li><li><a href=\"https://www.uptodate.com/contents/metachromatic-leukodystrophy/abstract/38\" class=\"nounderline abstract_t\">Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet 2016; 388:476.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6195 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H977153517\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H977153559\" id=\"outline-link-H977153559\">ETIOLOGY</a><ul><li><a href=\"#H2\" id=\"outline-link-H2\">Genetics</a></li></ul></li><li><a href=\"#H988968878\" id=\"outline-link-H988968878\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Late infantile onset</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Juvenile and adult onset</a></li><li><a href=\"#H1048028759\" id=\"outline-link-H1048028759\">Investigations</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">DIAGNOSIS</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">TREATMENT</a></li><li><a href=\"#H977153517\" id=\"outline-link-H977153517\">SUMMARY</a></li><li><a href=\"#H142975942\" id=\"outline-link-H142975942\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/6195|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/65871\" class=\"graphic graphic_algorithm\">- MRI algorithm white matter disorders</a></li></ul></li><li><div id=\"PEDS/6195|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/56567\" class=\"graphic graphic_table\">- Lysosomal storage disorders with peripheral neuropathy</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adrenoleukodystrophy\" class=\"medical medical_review\">Adrenoleukodystrophy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=alexander-disease\" class=\"medical medical_review\">Alexander disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=aspartoacylase-deficiency-canavan-disease\" class=\"medical medical_review\">Aspartoacylase deficiency (Canavan disease)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cerebrotendinous-xanthomatosis\" class=\"medical medical_review\">Cerebrotendinous xanthomatosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fabry-disease-neurologic-manifestations\" class=\"medical medical_review\">Fabry disease: Neurologic manifestations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=krabbe-disease\" class=\"medical medical_review\">Krabbe disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mucopolysaccharidoses-clinical-features-and-diagnosis\" class=\"medical medical_review\">Mucopolysaccharidoses: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-niemann-pick-disease\" class=\"medical medical_review\">Overview of Niemann-Pick disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pelizaeus-merzbacher-disease\" class=\"medical medical_review\">Pelizaeus-Merzbacher disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sjogren-larsson-syndrome\" class=\"medical medical_review\">Sj&ouml;gren-Larsson syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vanishing-white-matter-disease\" class=\"medical medical_review\">Vanishing white matter disease</a></li></ul></div></div>","javascript":null}